| P50 | author | Kunal Nepali | Q89110255 |
| | Ritu Ojha | Q99741360 |
| P2093 | author name string | Sahil Sharma | |
| | Jagjeet Singh | |
| | Harbinder Singh | |
| | Anu Ojha | |
| P2860 | cites work | 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia | Q24612292 |
| | Deciphering the inhibitory mechanism of genistein on xanthine oxidase in vitro. | Q53420327 |
| | Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors. | Q53600813 |
| | Microwave assisted synthesis of naphthopyrans catalysed by silica supported fluoroboric acid as a new class of non purine xanthine oxidase inhibitors. | Q54373597 |
| | Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. | Q55056789 |
| | Structure and Function of Xanthine Oxidoreductase | Q55982356 |
| | The influence of electronic, steric and hydrophobic properties of flavonoid compounds in the inhibition of the xanthine oxidase | Q58318980 |
| | Synthesis and xanthine oxidase inhibitory activity of 7-methyl-2-(phenoxymethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one derivatives | Q59140340 |
| | Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol | Q24652967 |
| | Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout | Q27023909 |
| | An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition | Q27639928 |
| | X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin | Q27694616 |
| | Urate-lowering therapy for gout: focus on febuxostat | Q28283310 |
| | Flavonoid glycosides isolated from unique legume plant extracts as novel inhibitors of xanthine oxidase | Q28481361 |
| | A practical approach to gout. Current management of an 'old' disease | Q33758862 |
| | How is gout managed in primary care? A review of current practice and proposed guidelines | Q33884300 |
| | Gout update: from lab to the clinic and back | Q33914121 |
| | Prevention and Management of Gout | Q34305913 |
| | Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers | Q34455863 |
| | Progress towards the discovery of xanthine oxidase inhibitors. | Q34541602 |
| | Febuxostat compared with allopurinol in patients with hyperuricemia and gout | Q34563183 |
| | Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects | Q34584089 |
| | Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout | Q34737229 |
| | A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? | Q34797671 |
| | Isolation and synthesis of biologically active carbazole alkaloids | Q34995236 |
| | Hydroxylated chalcones with dual properties: Xanthine oxidase inhibitors and radical scavengers | Q36535526 |
| | 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis | Q36870924 |
| | Molecular hybridization: a useful tool in the design of new drug prototypes | Q36879306 |
| | 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout | Q37277498 |
| | The treatment of hyperuricemia | Q38576552 |
| | Development of 2-(Substituted Benzylamino)-4-Methyl-1, 3-Thiazole-5-Carboxylic Acid Derivatives as Xanthine Oxidase Inhibitors and Free Radical Scavengers. | Q40314317 |
| | Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment. | Q40727676 |
| | Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency | Q40830127 |
| | Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production | Q42127578 |
| | Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia. | Q42714465 |
| | A comparative study of AutoDock and PMF scoring performances, and SAR of 2-substituted pyrazolotriazolopyrimidines and 4-substituted pyrazolopyrimidines as potent xanthine oxidase inhibitors | Q43206017 |
| | Insights into the inhibition of xanthine oxidase by curcumin | Q43267657 |
| | 2-Alkyloxyalkylthiohypoxanthines as new potent inhibitors of xanthine oxidase | Q43838644 |
| | Molecular modeling of flavonoids that inhibits xanthine oxidase | Q44021036 |
| | The reaction mechanism of xanthine oxidase: evidence for two-electron chemistry rather than sequential one-electron steps | Q44238301 |
| | Binding of xanthine oxidase to glycosaminoglycans limits inhibition by oxypurinol | Q44962055 |
| | Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers | Q45167605 |
| | Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial | Q46271681 |
| | The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase | Q46477429 |
| | 6-(N-benzoylamino)purine as a novel and potent inhibitor of xanthine oxidase: inhibition mechanism and molecular modeling studies | Q46737383 |
| | Identification of a potent xanthine oxidase inhibitor from oxidation of caffeic acid | Q46935245 |
| | Does starting allopurinol prolong acute treated gout? A randomized clinical trial | Q48089305 |
| | Quick identification of xanthine oxidase inhibitor and antioxidant from Erycibe obtusifolia by a drug discovery platform composed of multiple mass spectrometric platforms and thin-layer chromatography bioautography. | Q51076921 |
| | Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors. | Q51722188 |
| | Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. | Q52846892 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | xanthine oxidase inhibitor | Q8042974 |
| P304 | page(s) | 311-345 | |
| P577 | publication date | 2016-11-12 | |
| P1433 | published in | Expert Opinion on Therapeutic Patents | Q5421213 |
| P1476 | title | An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). | |
| P478 | volume | 27 | |